## REGN: Regeneron Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.15 indicates fundamental undervaluation. Quality metrics strong (ROE 15%). Consistent execution (3/4 quarters beat estimates). Caution: momentum weakening (-7.8% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($704.81)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Regeneron Puts Up $150M to Partner on Tessera Gene-Editing Med for Rare Liver & Lung Disorder**
- Source: MedCity News | 20251201T175100 | Somewhat-Bullish | Relevance: 99%
- Regeneron Pharmaceuticals is partnering with Tessera Therapeutics, committing $150 million to co-develop TSRA-196, a Phase 1-ready gene-editing therapy for alpha-1 antitrypsin deficiency (AATD). This collaboration aims to address the underlying cause of this rare liver and lung disorder, with Regeneron sharing development costs and profits, and Tessera overseeing initial clinical development. The deal highlights the growing interest in gene-editing approaches for AATD, positioning the companies alongside others exploring genetic and RNA-editing medicines.

**2. Regeneron (NASDAQ:REGN) in $150M Tessera pact on TSRA-196 AATD gene therapy**
- Source: Stock Titan | 20251201T070000 | Bullish | Relevance: 99%
- Regeneron (NASDAQ:REGN) and Tessera Therapeutics announced a global collaboration to develop TSRA-196, an investigational one-time gene editing therapy for alpha-1 antitrypsin deficiency (AATD). Tessera will receive $150 million upfront (cash plus equity) and is eligible for an additional $125 million in near/mid-term milestones, with the companies sharing development costs and future profits 50:50. Preclinical data showed durable SERPINA1 editing in mice and non-human primates, and Tessera expects to file IND and CTA submissions by year-end.

**3. Advisors Asset Management Inc. Cuts Stock Position in Regeneron Pharmaceuticals, Inc. $REGN**
- Source: MarketBeat | 20251129T081551 | Neutral | Relevance: 99%
- Advisors Asset Management Inc. reduced its stake in Regeneron Pharmaceuticals, Inc. by 16.4% in the second quarter, owning 4,488 shares valued at $2.36 million. Despite this, other hedge funds significantly increased their holdings, and institutional investors collectively own 83.31% of the company's stock. Regeneron reported strong quarterly earnings, beating consensus estimates, and announced a quarterly dividend.

**4. Somerville biotech secures $150M upfront from Regeneron for gene-editing treatment**
- Source: The Business Journals | 20251201T175140 | Bullish | Relevance: 99%
- Tessera Therapeutics, a Somerville-based biotech firm, has secured a $150 million upfront investment from Regeneron. This deal is intended to advance Tessera's experimental gene therapy for Alpha-1 Antitrypsin Deficiency (AATD) into clinical trials. The partnership aims to accelerate the development of this gene-editing treatment.

**5. Regeneron inks deal with Tessera to develop gene editing therapy**
- Source: Seeking Alpha | 20251201T152900 | Bullish | Relevance: 99%
- Regeneron Pharmaceuticals has partnered with privately held Tessera Therapeutics to develop the gene editing therapy TSRA-196 for alpha-1 antitrypsin, an inherited condition. The deal involves an upfront payment and an equity investment from Regeneron totaling $150M.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 5, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Wells Fargo | $745 | $700 | +6% |
| 2025-12-04 | Canaccord Genui | $1057 | $850 | +24% |
| 2025-12-04 | BMO Capital | $850 | $725 | +17% |
| 2025-12-03 | Morgan Stanley | $767 | $767 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Wells Fargo | main | Equal-Weight |
| 2025-12-04 | Canaccord Genui | main | Buy |
| 2025-12-04 | BMO Capital | main | Outperform |
| 2025-12-03 | Morgan Stanley | down | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($20.86M) |
| Sells | 5 ($11.41M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 8.8% (-4.0%)
- Blackrock Inc.: 8.6% (-4.7%)
- JPMORGAN CHASE & CO: 7.9% (+106.7%)
- State Street Corpora: 4.5% (-2.9%)
- Dodge & Cox Inc.: 4.4% (+18.9%)

### Key Risks

1. Heavy insider selling: $11M sold (5 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 5 raises (avg +16%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.15 suggests fair value with growth premium. Quality metrics strong (margin 32%). Balance sheet: strong liquidity (4.1x), low leverage (D/E 0.30), $1.4B free cash flow. Analyst sentiment positive (5 raises, avg +16%). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $77.0B |
| Beta | 0.37 |
| 52W Range | $476.49 - $790.98 |
| Short Interest | 2.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.15 |
| Forward P/E | 19.0 |
| Current P/E | 17.4 |
| YoY Growth | -8.5% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 13.0% to 5.2% (-7.8% in 5 days), indicating relative weakness vs NASDAQ. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 89th percentile. MRS_5 (-3.5%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 6.4% shows strong absolute momentum above own 20MA. Outperforming sector by 3.8pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (4.03), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 5.17% (CS: 90) | Strong |
| RSI_14 | 65.2 | Neutral |
| MACD Histogram | 4.03 | Bullish |
| vs SMA20 | 1.063x | Above |
| vs SMA50 | 1.183x | Above |
| vs SMA200 | 1.254x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $750.11
- **Stop Loss:** $704.81 (6.0% risk)
- **Target:** $840.71 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 16
- **Position Value:** $12,001.76
- **Portfolio %:** 12.00%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-02-03 (Est: $10.77)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $9.64 | $11.83 | +22.7% |
| 2025Q2 | $8.44 | $12.89 | +52.7% |
| 2025Q1 | $8.48 | $8.22 | -3.0% |
| 2024Q4 | $11.19 | $12.07 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*